Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis

Vivek Kumar1, Meghna Ailawadhi2, Navnita Dutta3

  • 1Department of Medicine, Brigham and Women's Hospital/Dana Farber Cancer Institute Boston, Boston, MA.

Abstract

Insights

Early mortality in multiple myeloma (MM) affects 21% of patients, with factors like older age and male gender increasing risk. While trends are improving, understanding these factors is crucial for better patient care.

Area of Science:

  • Hematology
  • Oncology
  • Epidemiology

Background:

  • Multiple myeloma (MM) treatment has advanced, yet early mortality (death within 6 months of diagnosis) remains a significant concern.
  • Rates and causes of early mortality in MM patients are variable and trends over time are not well-defined.

Purpose of the Study:

  • To analyze trends in early mortality for multiple myeloma patients.
  • To identify sociodemographic factors associated with early all-cause and MM-specific mortality.

Main Methods:

  • Utilized the Surveillance Epidemiology and End Results (SEER) database for MM cases diagnosed between 1975 and 2015.
  • Conducted multivariate analysis to assess sociodemographic factors linked to early mortality.
  • Employed joinpoint regression analysis to examine trends in early mortality over time.

Main Results:

  • Early mortality was observed in 21% of 90,975 MM patients; median age was 75 years in this cohort.
  • MM, cardiovascular disease, infections, and renal failure were leading causes of early death.
  • Increased risk of early mortality was associated with male gender, "other" race/ethnicity, older age, and specific US regions.

Conclusions:

  • Early mortality in multiple myeloma is a persistent challenge, despite recent improving trends.
  • Identifying risk factors is essential for developing personalized patient care strategies to mitigate early death.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
526
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
405
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
398
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
193